TOTAL: $275.35

Year to Date: $384.03M

Company
(Symbol)^#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)

AdipoGenix
Inc.*

Johnson & Johnson

ND

Milestone payment

Triggered by identification of the molecular target for a J&J compound discovered earlier in the companies' collaboration (3/14)

Aeolus
Pharmaceuticals
Inc. (OTC
BB:AOLS)

ARCA Discovery Inc.*

$0.35

Milestone payment

A cash payment and equity consideration were received based on Aeolus' ownership interest in CPEC LLC, which licensed bucindolol rights to ARCA (3/13)

Curis Inc.
(CRIS)

Procter & Gamble Pharmaceuticals

ND

Milestone payment

The first of two preclinical milestones was met in program to develop a topical Hedge- hog agonist for hair-growth disorders; Curis could earn $2.8M in preclinical milestones (3/21)

Evotec AG
(Germany;
FSE:EVT)

Boehringer Ingelheim GmbH (Germany)

ND

Milestone payment

Triggered by identification of a number of lead series for a receptor target, under their drug discovery deal (3/10)

ImClone
Systems Inc.
(IMCL)

Bristol-Myers Squibb Co.

$250

Milestone payment

Triggered by FDA approval of Erbitux for treating head and neck cancer (3/1)

Lexicon
Genetics Inc.
(LEXG)

Takeda
Pharmaceutical
Co. Ltd. (Japan)

$5

Milestone payment

Triggered by Takeda's selection of LG474 for development under their July 2004 deal focused on hypertension (3/2)

Millennium
Pharmaceuticals
Inc. (MLNM)

Johnson & Johnson

$10

Milestone payment

The payment was triggered by sales milestones reached for Velcade sales in territories outside the U.S. (3/9)

XenoPort Inc.
(XNPT)

Astellas Pharma
Inc. (Japan)

$10

Milestone
payment

Triggered by XenoPort's start of Phase III trials of XP13512 for treating restless legs syndrome (3/14)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company.

ND = Not disclosed.